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ABSTRACT 
Aspartate transcarbamoylase (ATCase) and Dihydroorotase (DHOase) catalyze the 
second and third steps, respectively, in de novo pyrimidine biosynthesis. Both enzymes form an 
active complex (DAC) in Aquifex aeolicus, where loop A of DHOase interacts with a domain of 
ATCase. The main objective of this work is to determine the function of specific residues of loop 
A in DAC interactions and to alter the catalytic activities through disruption of the interface 
between the two enzymes from A. aeolicus. The ATCase and DHOase domains have been 
expressed in Escherichia coli and purified using affinity chromatography. The interface of the 
published three-dimensional structure of the non-covalently associated dodecamer of DHOase 
and ATCase from A. aeolicus was examined using bioinformatics, and a peptide was designed to 
block a specific hydrophobic region. In this work, several peptides have been synthesized by 
solid phase peptide synthesis (SPPS). Assays were conducted to determine the binding affinities 
of the peptides to the DHO-ATC complex.  
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CHAPTER 1: INTRODUCTION 
 
Introduction 
Cancer is a disorder which involves uncontrolled cell division, resulting in a 
destruction of body tissue. In the United States, cancer is the second highest cause for 
deaths, with nearly one in every four people falling victim to it. Based on the data 
provided by the American Cancer Society in its 2014 cancer incidence statistics, more 
than 1,500,000 new cancer cases and more than 500,000 cancer deaths were estimated. 
How does cancer form? Each cell in the body has DNA that carries the cell’s 
information. If the DNA becomes damaged, the cell will not function normally. Cancer 
starts when these abnormal cells start dividing uncontrollably,1 and there are many 
mechanisms that these cancer cells employ to divide without any regulatory control.  
Pyrimidine nucleotides have a major role in cell growth.2,3 In cancer, de novo 
pyrimidine biosynthesis is upregulated. Thus, there is need for effective 
chemotherapeutic agents that act by targeting the enzymes that catalyze this pathway in 
the earliest steps.4 Understanding the role of the pyrimidine pathway in the rapid growth 
of tumors can be achieved, in part, by understanding the process of pyrimidine de novo 
biosynthesis in prokaryotic cells. The analogous pyrimidine biosynthetic enzymes from 
the A. aeolicus bacteria are used as a model system because of their known homology 
with the mammalian counterparts.  Targeting the enzymes involved in the second and 
third steps of this pathway in A. aeolicus may lead to the development of new drugs for 
cancer in the long run. 
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Pyrimidine Pathway 
The pyrimidine pathway performs a major role in cell metabolism by activating 
the precursors of DNA and RNA, CDP-triacylglycerol, and phosphoglyceride, which are 
needed for assembling cell membranes, and the precursors needed for the glycosylation 
of proteins and the synthesis of glycogen by UDP-Glucose. Moreover, the uridine 
nucleotide, which is formed by pyrimidine biosynthesis,2 regulates a different 
physiological process through extracellular receptors.3 Pyrimidine synthesis has two 
different paths: the nucleotides can be reused by the salvage pathway, or they can be 
synthesized de novo from small metabolites.2,3 The activation of these paths to 
pyrimidine synthesis depends on the cell type, its growth phase, and its developmental 
stage. In fully differentiated cells or in the resting stage, the rate of the de novo synthesis 
is low because the required pyrimidine level is met by the salvage pathway. In contrast, 
the rate of the de novo pyrimidine synthesis is high in proliferating cells in order to meet 
the increased demand for the precursors of DNA and RNA, along with other 
components.5 Therefore, better understanding of the de novo activity of pyrimidine 
biosynthesis is necessary to elucidate the regulation of the growth-state-dependent 
control mechanisms of this pathway and their breakdown and failure in cancer.   
De novo Pyrimidine Biosynthesis 
The pyrimidine de novo biosynthetic pathway effectively serves the rapid growth 
of tumors.2 It is carried out by six enzymatic steps to form Uridine 5'-monophosphate 
(UMP). The first three steps in pyrimidine de novo biosynthesis in mammalian cells are 
catalyzed by three enzymes, Carbamoyl-phosphate synthetase II (CPSase II), Aspartate 
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transcarbamoylase (ATCase), and Dihydroorotase (DHOase), referred to as CAD. These 
enzymatic activities are all carried on a single polypeptide chain that forms carbamoyl 
phosphate, carbamoyl aspartate, and dihydroorotate, respectively. These steps are 
chemotherapeutic targets, since they catalyze the first steps of the pathway.  The rest of 
the pyrimidine pathway is catalyzed by dihydroorotate dehydrogenase (DHOdhase), 
UMP Synthase (UMPSase), and CTP synthase (CTPSase) to form orotate, UMP, and 
CTP, respectively (Figure 1).6,7 CAD is the key regulatory enzyme in mammalian de 
novo pyrimidine biosynthesis because it catalyzes the first rate limiting step of the 
pathway.  
 
Figure 1: The de novo pyrimidine biosynthetic pathway.3 
Aquifex aeolicus 
A. aeolicus belongs to the Aquificales order, and is gram-negative with no capability 
to form spores. Aquificales are hyperthermophilic bacteria that live in hot springs, both 
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terrestrial and marine. Aquificales are autotrophs as they can use inorganic substances to 
form nutritional organic substances.8 A. aeolicus is an extreme hyperthermophilic organism 
with an ancient lineage. This bacteria grows in temperatures reaching up to 95°C, in a CO2, 
O2, and H2 atmosphere.9 This property gives the enzymes from A. aeolicus great stability in 
the face of changes in temperature, pressure, and levels of O2. This stability is an attractive 
feature for research studies involving enzyme activity.  
 
Figure 2: Comparison of the structural organization of the enzymes catalyzing the first 
three steps of the de novo pyrimidine biosynthesis in mammals, A. aeolicus, and E. 
coli.11 
CAD Complex vs. Aquifex aeolicus Enzymes 
The first three steps in de novo pyrimidine biosynthesis in mammals are 
catalyzed by CAD.2,3 In prokaryotic cells, the enzymes involved in the pathway are 
encoded by separate genes and have separate expressions. These enzymes can function 
independently, such as in E.coli, or can be associated with a multifunctional complex as 
in the case of A. aeolicus (Figure 2).10 The latter is similar in function to the mammalian 
complex. Unlike the mammalian enzymes, the first three enzymes in the de novo 
pyrimidine biosynthesis in A. aeolicus are monofunctional proteins. Furthermore, unlike 
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the mammalian system, the first step catalyzed by the bacterial CPSase is not the 
committed step as it catalyzes the formation of carbamoyl phosphate for both pyrimidine 
and arginine biosynthesis.12 Therefore, the function of the second enzyme ATCase is 
likely to be the first committed step in pyrimidine biosynthesis in A. aeolicus to catalyze 
the formation of carbamoyl aspartate.3,12   The third enzyme DHOase catalyzes the 
reversible step to form dihydroorotate from carbamoyl aspartate. This activity is 
typically 10 fold lower than that of ATCase.    
 
Figure 3: The second and third steps in pyrimidine biosynthesis. (A) ATCase catalyzes 
the condensation of carbamoyl phosphate and aspartate to form carbamoyl aspartate and 
phosphate. (B) DHOase catalyzes the formation of dihydroorotate and water from 
carbamoyl aspartate and H+.11,13 
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Figure 4: ATCase structure. (A) The residues at the interface between the carbamoyl 
phosphate and aspartate domains (Lys 26 and Lys 138, yellow, space filled) are shown. 
(B) A major residue for the two substrate binding (Lys 75, blue, space filled) is shown. 
(C) The active site residues (Gln 219, Val 190, Phe 191, Leu 8, Gly 122, and Phe 103, 
blue, space filled) are shown. This figure was prepared using PyMol viewer (PDB Id: 
3B6N).13 
Aspartate Transcarbamoylase in Aquifex aeolicus 
ATCase catalyzes the formation of carbamoyl aspartate in the second step of 
pyrimidine biosynthesis (Figure 3.A). ATCase in bacteria is classified into three groups 
based on the number of subunits and the molecular mass. Class A is defined by the 
association of two trimers and six DHOase monomers to form 480-kDa dodecamers, 
e.g., Pseudomonas aeruginosa ATCase. In class B, there is association of two trimers 
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and three regulatory dimers to form 310-kDa dodecamers, e.g., E. coli ATCase. Class C 
is usually characterized by 100-kDa trimers, e.g., Bacillus subtilis.13 Interestingly, 
ATCase in A. aeolicus differs from these classifications.   A. aeolicus ATCase, a 34-kDa 
subunit, is encoded by the gene pyrB. ATCase has two domains, namely, carbamoyl 
phosphate and aspartate, connected internally through Lys 26 and Lys 138 (Figure 4). 
ATCase in A. aeolicus is inactive as a monomer, and only functions when it forms a 
trimer.13 
 
Figure 5: The structure of A. aeolicus DHOase. It is an inactive monomer presumably 
due to the intrinsically disordered loop (Loop A, green) blocking any access to the 
active site. DHOase has a single zinc ion (yellow). This figure has been prepared using 
the PyMol viewer (PDB Id: 1XRF). 
Dihydroorotase Structure in Aquifex aeolicus 
The first crystal structure of A. aeolicus DHOase allows its classification as a 
type I dihydroorotase.14 This classification is based on the number of zinc ions and their 
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function in DHOase, which is same as the DHOase domain in the mammalian CAD.3,14 
The sequence homology between the DHOase domain of the mammalian CAD and A. 
aeolicus DHOase is about 26% .11,14 This homology is higher, between the DHOase in 
Aquifex aeolicus and mammalian CAD,  than that found when compared to other 
bacteria. For example, E. coli 15 DHOase has13% sequence homology with the DHOase 
domain of CAD.11,14 These similarities demonstrate that Aquifex aeolicus can be used as 
a model system to study the enzymes involved in de novo pyrimidine biosynthesis. 
 
Figure 6: One ATCase monomer complexed with one DHOase monomer of the 
dodecameric DHO-ATC complex (DAC). 
DHO – ATC Complex  
The first crystal structure of the dodecameric complex of dihydroorotase and 
aspartate transcarbamoylase from A. aeolicus was solved in 2009.10 This structure is 
predicted to be a possible model of mammalian CAD since it is the first structure of a 
multienzyme complex in the pyrimidine pathway.10,11,14 Also, the active site of DHOase 
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in A. aeolicus has only one zinc atom, Znα. This zinc atom shows a square-pyramidal 
geometry with four amino acid residues: His-61, His-63, Asp-153, Asp-305, and one 
water molecule, all as ligands.11,14 Moreover, the metal binding signature sequence is 
exactly the same as in CAD and differs by only one residue in E. coli. Although there is 
a second zinc site, the absence of the second zinc ion does not seem to affect the 
reversible reaction of carbamoyl aspartate to form dihydroorotate (Figure 3.B). Thus, 
DHOase is activated by a mononuclear metal ion.15,16 Nevertheless, the DHOase in A. 
aeolicus is inactive and only becomes active on association with ATCase, despite the 
binding of the zinc.11,14 There are three factors which may explain why the isolated 
enzyme DHOase in A. aeolicus, is inactive (Figure 5). First, there is no access to the 
active site because of the bond between the Znα and Cys181. This blocking interaction is 
not found in the DHOase in E.coli. Second, it may be because of the absence of the 
second zinc atom in DHOase in A. aeolicus, although recent studies suggest that it is not 
essential for catalytic activity.16 Third, there are three loops that have intrinsic disorders 
around the active site that are likely blocking any access to it.10 The importance of these 
three factors is highlighted in the structure of the stoichiometric complex of DHOase 
associating with ATCase in A. aeolicus.10 The complex is a hetero dodecamer that forms 
an unfilled space or cavity on the inside. The ATCase – DHOase complex (DAC) is 
formed by two trimers of ATCase and three dimers of DHOase enzymes, 12 enzymes in 
total, where all the active sites are facing the internal, aqueous phase. This specific 
organization appears to facilitate the interaction between the active sites and activates the 
DHOase in order to catalyze the third step in the de novo pyrimidine biosynthetic 
pathway that results in the formation of dihydroorotate.10 Upon complex formation, 
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Loop A of DHOase interacts with the ATCase domain rendering the DHOase active site 
accessible (Figure 6).17  
Importance of Loop A 
Recently, enzyme assays were conducted to determine the binding affinities of 
synthetic peptides from certain regions of loop A to DAC in A. aeolicus.17 The peptides 
were used in different concentrations to determine the stoichiometry of the peptide-
protein complex. The results indicated that the peptide, NEGEVSALLGLS, inhibited the 
functional interaction of DAC in an allosteric manner.  This peptide, which is part of 
loop A, was shown to alter the catalytic activities of the DAC complex likely through the 
disruption of the interface between the DHOase and ATCase domains.17 These results 
provided a promising lead on the potential of loop A as a noncompetitive drug target to 
control the second and third steps in de novo pyrimidine biosynthesis. The peptide, 
DHCEDDKLA, may serve as a competitive inhibitor because it may bind directly to the 
active site on the DHOase domain. However, the competitive inhibitor function of this 
region of loop A has not been tested prior to this study.  
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Hypothesis 
In loop A, residues 179 – 186 are involved in competitively inhibiting the DHOase 
active site while residues 192 – 203 noncompetitively inhibit the ATCase active site. 
 
179 DHCEDDKLAYGVINEGEVSALLGLSSRAPEAE 210 
 
Goals 
1. To determine the function of specific residues of loop A in DAC functional 
interactions. 
2. To alter the catalytic activities through disruption of the interface between the two 
enzymes from A. aeolicus. 
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CHAPTER 2: EXPERIMENTAL METHODS 
Peptide Synthesis 
The SPPS method was used to synthesize the peptide. 0.4 mmol amino acid, 
protected by N-α-fluorenylmethyloxycarbonyl (Fmoc), and 0.4 mmol activating agent 
hydroxylbenzotriazolyltetramethyluronium hexafluorophosphate (HBTU) (4X excess) 
were added into a vial. 0.1 mmol of p-methylbenzhydrylamine (MBHA) resin was used 
as the solid support to give a carboxamide terminus. The PS3 synthesizer was 
programmed to couple amino acids, remove each Fmoc group, and wash with N,N-
dimethylformamide (DMF) at each step.  In order to cleave the peptide from the resin, 
the peptide was treated by adding 0.5 mL distilled water, 0.5 mL phenol scavenger, and 
10 mL trifluororacetic acid (TFA). The peptide resin was stirred for two hours at room 
temperature. The peptide-containing solution was then removed from the resin through 
filtration, following which cold diethyl ether was added for peptide precipitation. The 
precipitant, the solid peptide, was collected by filtration and then dissolved in 35% 
ACN/H2O and lyophilized. The peptides were dissolved in methanol first, and then the 
resultant solution was purified by reverse-phase high performance liquid 
chromatography (RP-HPLC) using an absorbance wavelength of 214 nm for detection. 
The peptide solution was injected and run with linear gradient of 10 – 50% ACN in H2O 
over two hours. The solution was collected in test tubes where peaks were observed. The 
tubes containing pure peptide were combined and lyophilized before the purity was 
confirmed by RP-HPLC. Electrospray ionization mass spectrometry (ESI-MS) was used 
to confirm the molecular weight of the peptides. The resultant peptides were dissolved in 
100% dimethyl sulfoxide (DMSO) with a final concentration of 2 mg/mL. 
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Protein Expression 
The pyrB and pyrC genes encoding A. aeolicus ATCase and DHOase were 
cloned into an expression vector, pRSET, to purify the expressed protein with His-tag on 
a Nickel resin. 3 μL of the plasmids pAApyrB and pAApyrC were transformed in a vial 
with 40 μL of the competent cells (the E. coli strain BL21 (DE3*)) along with 5 μL of 
helper plasmid pSJS1240. The mixture was incubated in ice for 30 min. The E. coli were 
heat shocked for exactly 30 seconds in a 42°C water bath. 250 μL of pre-warmed SOC 
medium was added to the E. coli cells. The vials were placed in a shaker at 37°C, 220 
rpm, for one hour. The transformed cells were placed on a pre-prepared LB agar plate 
containing 100 μg/mL ampicillin and 50 μg/mL spectinomycin, and grown at 37°C 
overnight. After growing the cells overnight, the cells were centrifuged at 13,000 rpm at 
4°C for 30 min. The medium was discarded and the pellets were re-suspended in 3 mL of 
50 mM Tris/Cl buffer. Sonication was applied to disrupt the cells 6 times for 30 seconds. 
The extracted cells were centrifuged at 13,000 rpm at 4°C for 30 min.  
The recombinant protein was purified by Ni2+ affinity chromatography as the 
proteins were expressed with a His tag. The supernatant was applied to a 1 mL Ni2+-
ProBond column equilibrated with 50 mM Tris-HCl and 200 mM NaCl (TN buffer). The 
proteins were eluted with successive 1 mL aliquots of increasing concentrations of 
imidazole from 50 to 400 mM in TN buffer and the fractions were collected. Analysis of 
the fractions was accomplished by Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) with 10% acrylamide. Fractions containing pure A. 
aeolicus ATCase and DHOase were applied to the bicinchoninic acid (BCA) assay kit to 
determine protein concentration. 
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Enzyme Assays 
 For the ATCase assay, the enzyme activity was measured by a colorimetric 
method where the assay was performed as a function of enzyme concentration. The 
samples were prepared by adding 500 μL of assay buffer (3 ml of 0.5 M Tris, 0.25 mL 
aspartate, and H2O up to15 mL), enzyme (two assays, ATCase only and ATCase in 
DAC, ATC-DHO, 2:3 ratio), and H2O up to 1 mL in culture tubes. The sample reactions 
were initiated by adding the substrate (100 μL of 50 mM carbamoyl phosphate), mixed 
and placed in a 70°C water bath. The total assay time was 3 min. After 3 min, 1 mL of 
5% acetic acid was added to quench the reaction, followed by mixing and placement at 
room temperature. 2 mL of color mix (antipyrine and monooxime, 1:2 ratio) was added 
to each tube, which acted as an indicator for the product carbamoyl aspartate. 
Absorbance at 466 nm of carbamoyl aspartate was measured after 60 min incubation at 
60°C. Another ATCase assay was performed as a function of peptide concentration. The 
peptides DHCEDDKLA and NEGEVSALLGLS were added at different concentrations. 
 For DHOase, the assay was performed as a function of enzyme concentration. 
The samples were prepared by adding 500 μL of assay buffer (0.1 M Tris), enzymes 
(DAC, ATC-DHO, 2:3 ratio), and H2O up to 1 ml in culture tubes. The sample reactions 
were initiated by adding the substrate (50 μL of 80 mM dihydroorotate), mixed and 
placed in a 70°C water bath. The assay proceeded as has been described in the ATCase 
assay section. 
15 
 
 In all assays, the concentration of carbamoyl aspartate was calculated from 
standard curves created with known concentrations of 10 mM carbamoyl aspartate. The 
data plot is linear.  
PyMol Viewer  
 Enzyme structures were visualized and modeled by the PyMol viewer software. 
First, the structure was downloaded from a protein data bank website as a PDB File 
(Text). From the PyMol molecular graphics system window, the sequence was displayed 
in order to select the desired residues. The sequence appeared on the top of the PyMol 
viewer window. Different commands (Action, Show, Hide, Label, and Color) from the 
PyMol Names Panel were used to make the desired changes to the structure. The desired 
residues within specific distances were selected. On the structure (the selected residues 
are marked), the “actions” option appeared on a right-click of the mouse. The following 
options were used: “around” and “residues within 4, 5, and 6 Å”    
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CHAPTER 3: RESULTS AND DISCUSSION 
Loop A, part of DHOase, has been reported as a significant loop by which 
DHOase and ATCase activities are functionally coupled, and loop A appeared to be 
wedged between the two ATCase domains. The residues of loop A are believed to have 
separate effects based on the location of these residues. It is critical to identify the 
specific function of these residues in order to potentially regulate the enzyme activity 
with greater control. Moreover, the specific function can be identified by determining 
where and how specific parts of loop A bind to specific regions between these two 
enzymes (Figure 7).  
 
Figure 7: Loop A of DHOase. The sequence of loop A (top) in different colors 
corresponds to those in the structure (bottom). 
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The peptides HCE, DHCEDD, DHCEDDKLA, and NEGEVSALLGLS were 
prepared using the PS3 synthesizer with high purity of 99 to 100% after purification.  
The purification of the peptides was confirmed by RP-HPLC. The peptide yield on SPPS 
is generally around 20 to 50%, and different yield percentages were obtained 
experimentally (Table 1). The peptides were identified by ESI-MS and dissolved in 
DMSO with a final concentration of 2 mg/mL.  
Table 1: Synthetic peptide yields 
 
 The A. aeolicus ATCase protein was expressed in E. coli BL21 (DE3*) and 
purified using Ni2+ affinity chromatography.  Subsequent to extensive washing, about 
2/3 of the ATCase protein was eluted with 200 mM imidazole/TN buffer and a third was 
eluted with 300 mM imidazole/TN buffer. The molecular mass of the purified ATCase 
corresponded to 34-kDa as compared to the protein ladder, a reference to determine the 
mass of the unknown protein (Figure 8).     
 The DHOase protein from A. aeolicus was expressed in E. coli BL21 (DE3*). 
The purification was accomplished by Ni2+ affinity chromatography. About 75% of the 
protein was eluted with 200 mM imidazole/TN buffer and the rest of the total protein 
Peptide Percent yield 
HCE 31 % 
DHCEDD 33 % 
DHCEDDKLA 48 % 
NEGEVSALLGLS 25 % 
18 
 
was eluted with 300 mM imidazole/TN buffer. As compared to the ladder, the 
molecular mass corresponded to that reported in the literature, 46-kDa (Figure 9). 
 
Figure 8: SDS-PAGE gel of A. aeolicus ATCase expression, purified by Ni2+ affinity 
chromatography.  
 
Figure 9: SDS-PAGE gel of A. aeolicus DHOase expression, purified by Ni2+ affinity 
chromatography.  
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The effect of the peptide NEGEVSALLGLS has been reported previously as an 
allosteric noncompetitive inhibiter.18 The peptide acted by mimicking the end segment of 
loop A in DHOase in order to diminish the interaction necessary with ATCase. 
Interestingly, the activity of the isolated ATCase subunit was more affected by the 
peptide NEGEVSALLGLS than the ATCase activity in DAC. The catalytic activity of 
both the ATCase and DHOase were affected (Figures 10, 11). Percent inhibition of the 
peptide was variable (Table 2), which helped raise several questions, such as: a) Which 
one of these enzymes is most affected by the peptides? b) How does the DAC complex 
modulate the effect of the peptides on the isolated enzymatic components?  c) Which 
part of loop A affects only the ATCase or DHOase activities? 
 
Figure 10: The ATCase assay and the effect of the peptide as a function of increasing 
enzyme concentration. The peptide used is NEGEVSALLGLS (orange) (A) The 
ATCase activity of the isolated ATCase subunit (green). (B) The ATCase activity of 
DAC (blue). 
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The effect of the peptides reflecting different regions of loop A on the activity of 
the isolated ATCase subunit was measured by measuring the ATCase activity. The 
enzymatic assay was performed at a variety of enzymes concentrations. Different 
peptides representing unique and/or overlapping regions of the first segment of loop A, 
residues 179 – 186, were synthesized (HCE, DHCEDD, DHCEDDKLA). In the case of 
all the peptides above, the effect on the isolated ATCase activity was not evident in the 
region of lower protein concentrations.  No effect was observed upon the addition of the 
peptides (HCE, DHCEDD, DHCEDDKLA) to lower concentrations of the isolated 
ATCase domain (2.5 μL of 0.164 μg/mL) suggesting a concentration-dependence 
response to the peptides (Figure 12).  Increasing the concentration of the protein, 
however, showed the inhibitory effect of the peptides on the isolated ATCase activity 
(Table 2).  
 
Figure 11: The DHOase activity inhibition of DAC as a function of increasing enzyme 
concentration. DHOase activity in the absence of peptide (black) and the presence of the 
peptide NEGEVSALLGLS (orange). 
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Figure 12: The activity of the isolated ATCase subunit as a function of increasing 
enzyme concentration. The isolated ATCase subunit activity (green) and the effect of 
different peptides (orange). (A) HCE peptide. (B) DHCEDD peptide. (C) 
DHCEDDKLA peptide.  
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Figure 13: The ATCase activity of DAC inhibited by short peptides. The activity of 
ATCase of DAC (blue) and the effect of different peptides (orange) as a function of 
increasing enzyme concentration. (A) HCE peptide. (B) DHCEDD peptide. (C) 
DHCEDDKLA peptide.  
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Figure 14: The DHOase activity of DAC inhibited by short peptides. The activity of 
DHOase of DAC (black) and the effect of different peptides (orange) as a function of 
increasing enzyme concentration. (A) HCE peptide. (B) DHCEDD peptide. (C) 
DHCEDDKLA peptide.  
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Similar percent inhibitions were observed for the peptides’ effect on the activity 
of ATCase in the DAC complex.  The DAC complex was prepared by the addition of 2.5 
μL of (0.164 μg/μl) ATCase and (0.238 μg/μl) DHOase (2:3 ratio) and the peptides (with 
final concentration 0.2 mg/ml) were added (Figure 13).  The percent inhibition of the 
ATCase activity in the DAC complex were found to be in the same range as in those 
observed with the isolated subunit. 
The effects of the peptides, HCE, DHCEDD, DHCEDDKLA, on the activity of 
DHOase of DAC was measured starting at the lowest concentration, 2.5 μL of (0.164 
μg/μL) ATCase/ (0.238 μg/μL) DHOase (2:3 ratio), and with increasing enzyme 
concentration (Figure 14). The effects are similar to those found on the ATCase activity 
of DAC; however, the percent inhibition on DHOase of DAC activities varies between 
these peptides, which reflects the effect of the specific residues on the DHOase activity 
of DAC. 
Table 2: Peptides effect (inhibition %) on the isolated ATCase subunit, ATCase of 
DAC, and DHOase of DAC. 
 
Peptide 
ATCase activity 
inhibition % 
(ATCase) 
ATCase activity 
inhibition % 
(DAC) 
DHOase activity 
inhibition % 
(DAC) 
HCE 43.7 25.8 35.1 
DHCEDD 5.26 24.2 23.4 
DHCEDDKLA 38.3 29.3 40.6 
NEGEVSALLGLS 44.2 29.3 10.9 
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Figure 15: Percent of ATCase activity as a function of increasing peptide concentration. 
The effect of the peptides NEGEVSALLGLS (orange) and DHCEDDKLA (blue) was 
determined (A) The ATCase activity of the isolated ATCase subunit. (B) The ATCase 
activity of DAC.  
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The effect on the ATCase activity of increasing peptide concentration (0.1, 0.3, 
0.4, and 0.5 mg/mL) was different between the isolated ATCase subunit activity and the 
ATCase activity of DAC. The peptide, DHCEDDKLA, affects the isolated ATCase 
subunit activity more than the peptide, NEGEVSALLGLS. The ATC activity of DAC 
with NEGEVSALLGLS, however, has more of a dependence upon the peptide 
concentration as compared to the effect of the peptide, DHCEDDKLA, which does not 
seem to have a significant effect on the ATCase activity of DAC (Figure 15). 
All of the results are summarized in Tables 3 and 4. 
 
Figure 16: The residues of the ATCase active site interacting with part of loop A, 
NEGEVSALLGLS (white). 
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Figure 17: Part of loop A interaction with the metal binding residues in the DHOase. 
Table 3: Peptide effect on ATCase activity. 
Peptide 
ATCase 
inhibition 
% 
(alone) 
ATCase 
inhibition 
% 
(DAC)  
Data Interpretation 
   HCE 43.7 25.8 
• DHOase is protecting against the 
inhibition of ATCase by HCE  
• It might be a concentration 
dependence 
DHCEDD 5.26 24.2 
• DHCEDD is poor inhibitor of 
ATCase alone but not in DAC 
• The effect could be due to inhibition 
of DHOase 
DHCEDDKLA 38.3 29.3 
• The extra residues KLA are important 
in restoring the inhibition by HCE 
• The negative charge of D’s is not 
inhibiting  
NEGEVSALLGLS 44.2 29.3 
• Inhibits ATCase non-competitively  
• DHOase protects ATCase from the 
inhibition 
• It might be a concentration 
dependence  
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Table 4: Peptide effect on DHOase activity. 
Peptide 
DHOase 
inhibition 
% 
(DAC) 
Data Interpretation 
   HCE 35.1 
• The peptide  HCE inhibits DHOase 
• HCE is the minimum region needed to inhibit the 
DHOase 
DHCEDD 23.4 
• It is possible that DHCEDD inhibits DHOase 
which explain the inhibition of ATCase in DAC 
DHCEDDKLA 40.6 
• The positive region K increase the inhibition of 
DHOase  
NEGEVSALLGLS 10.9 
• The inhibition might be indirect, through ATCase 
inhibition, with a small effect on DHOase 
inhibition 
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CHAPTER 4: CONCLUSIONS AND RECOMMENDATIONS 
The DHOase appears to be protective against the inhibition of ATCase by HCE, 
and it might be a concentration dependent effect. DHCEDD is a poor inhibitor of 
ATCase alone, but not in DAC. The effect could be due to the inhibition of DHOase. 
The extra residues, KLA, are important in restoring the inhibition by HCE. The negative 
charge of the D residues is not inhibiting. Moreover, the peptide HCE inhibits DHOase. 
HCE is the minimum region needed to inhibit the DHOase. It is possible that DHCEDD 
inhibits DHOase, which explains the inhibition of ATCase in DAC. The positive region 
provided by K increases the inhibition of DHOase. Additionally, the peptide 
NEGEVSALLGLS inhibits ATCase non-competitively and DHOase protects ATCase 
from this inhibition. The inhibition of DHOase activity of DAC by NEGEVSALLGLS 
might be indirect, through ATCase inhibition, with small effects on DHOase inhibition 
(Tables 3 and 4). 
Further studies are needed to confirm these results. These may be achieved by 
performing dihydroorotate saturation curves with and without peptides, specifically 
HCE, to calculate and observe the effect on Km. Also, it is crucial to find the minimum 
sequence of NEGEVSALLGLS that can serve as a non-competitive inhibitor with high 
affinity. It is important to construct DHCEDDKLA with changes in HCE and mutate 
HCE one residue at a time.  
Proposed peptides for future work are suggested as follows: (a) residues that 
interact with the ATCase active site (Figure 16); GEVSALLG at 4 Å, EGEVSALLGL at 
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5 Å, and EGEVSALLGLS at 6 Å, (b) residues at the DHOase active site (Figure17); 
D*CEDDKLA, DH*EDDKLA, and DHC*DDKLA (where * is a mutant residue). 
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